1Departments of Neurosurgery.
2Epidemiology and Public Health.
Neurosurg Focus. 2024 Nov 1;57(5):E4. doi: 10.3171/2024.8.FOCUS24460.
Laser interstitial thermal therapy (LITT) is an emerging tool for treating a variety of focal brain lesions, including recurrent high-grade glioma (HGG). While the efficacy and uses of LITT have been well studied, the impact of this treatment on patient functional outcomes has not been analyzed in detail. This study sought to better define the role of LITT in treating patients with recurrent HGG, examining which patients exhibit good functional outcomes after LITT, and to determine risk factors for worsening neurological function.
The medical records of patients treated with LITT for recurrent HGG at a single tertiary care center were retrospectively reviewed. Functional status was assessed using the Karnofsky Performance Scale (KPS). Demographic, clinical, and radiological data were examined for associations with change in KPS score assessed 4-6 weeks following surgery.
Forty-seven patients were included in the study with histopathologically confirmed recurrent HGG. The mean age was 57 years, and 21 (45%) patients were female. The pre-LITT KPS scores were as follows: 100 in 4 (9%) patients, 90 in 15 (32%) patients, 80 in 10 (21%) patients, 70 in 13 (28%) patients, and 60 in 5 (11%) patients. Overall, 59% of patients showed a stable or improved KPS score after undergoing LITT. Tumor volume was the sole predictor of decreased KPS score after LITT. Notably, tumor location including eloquent location, preoperative KPS score, and other comorbidities were not independently associated with change in functional status.
The majority of patients undergoing LITT for recurrent HGG had a favorable functional outcome at the initial follow-up visit. The treated tumor volume was inversely and independently associated with post-LITT functional outcome. This information may help guide patient selection and treatment optimization in the setting of LITT-based approaches for recurrent HGG.
激光间质热疗(LITT)是一种新兴的治疗各种局灶性脑病变的工具,包括复发性高级别胶质瘤(HGG)。虽然 LITT 的疗效和用途已经得到了充分的研究,但这种治疗方法对患者功能结局的影响尚未进行详细分析。本研究旨在更好地定义 LITT 在治疗复发性 HGG 患者中的作用,研究哪些患者在 LITT 后表现出良好的功能结局,并确定神经功能恶化的危险因素。
回顾性分析了一家三级医疗中心采用 LITT 治疗复发性 HGG 的患者的病历。采用 Karnofsky 表现量表(KPS)评估功能状态。对人口统计学、临床和影像学数据进行了检查,以确定与术后 4-6 周 KPS 评分变化相关的因素。
本研究共纳入 47 例经组织病理学证实的复发性 HGG 患者。患者平均年龄为 57 岁,21 例(45%)为女性。LITT 前 KPS 评分如下:9 分(9%)4 例,8 分(32%)15 例,7 分(21%)10 例,6 分(28%)13 例,5 分(11%)5 例。总体而言,59%的患者在接受 LITT 后 KPS 评分稳定或改善。肿瘤体积是 LITT 后 KPS 评分下降的唯一预测因素。值得注意的是,肿瘤位置(包括功能区位置)、术前 KPS 评分和其他合并症与功能状态的变化无关。
大多数接受 LITT 治疗复发性 HGG 的患者在初始随访时功能结局良好。治疗后的肿瘤体积与 LITT 后功能结局呈负相关且独立相关。这些信息可能有助于指导 LITT 治疗复发性 HGG 的患者选择和治疗优化。